BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2272-9. [PMID: 21784820 DOI: 10.2215/CJN.01650211] [Cited by in Crossref: 68] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012;206:1558-67. [PMID: 23066162 DOI: 10.1093/infdis/jis545] [Cited by in Crossref: 145] [Cited by in F6Publishing: 145] [Article Influence: 14.5] [Reference Citation Analysis]
2 Sharaf El Din UAA, Salem MM, Abdulazim DO. FGF23 and inflammation. World J Nephrol 2017; 6(1): 57-58 [PMID: 28101453 DOI: 10.5527/wjn.v6.i1.57] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D’Haese PC, Neven E. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int. 2013;83:1109-1117. [PMID: 23486515 DOI: 10.1038/ki.2013.34] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
4 Kubotera N, Prokopienko AJ, Garba AO, Pai AB. Endotoxin binding by sevelamer: potential impact on nutritional status. Int J Nephrol 2013;2013:954956. [PMID: 23401772 DOI: 10.1155/2013/954956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
5 Donate-Correa J, Martín-Núñez E, Ferri C, Hernández-Carballo C, Tagua VG, Delgado-Molinos A, López-Castillo Á, Rodríguez-Ramos S, Cerro-López P, López-Tarruella VC, Arévalo-González MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF. FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus. J Clin Med 2019;8:E448. [PMID: 30987161 DOI: 10.3390/jcm8040448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
6 Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol 2016;4:598-610. [PMID: 26873066 DOI: 10.1016/S2213-8587(15)00388-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
7 Riccio E, Sabbatini M, Bruzzese D, Grumetto L, Marchetiello C, Amicone M, Andreucci M, Guida B, Passaretti D, Russo G, Pisani A. Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol 2018;22:529-38. [PMID: 29159529 DOI: 10.1007/s10157-017-1504-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
8 Sharaf El Din UAA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol 2016; 5(5): 398-417 [PMID: 27648404 DOI: 10.5527/wjn.v5.i5.398] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
9 Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther 2013;10:29. [PMID: 24330529 DOI: 10.1186/1742-6405-10-29] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
10 Díaz-De la Cruz EN, Cerrillos-Gutiérrez JI, García-Sánchez A, Prado-Nevárez CG, Andrade-Sierra J, Jalomo-Martínez B, Banda-López A, Rojas-Campos E, Miranda-Díaz AG. The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up. Front Med (Lausanne) 2021;8:714205. [PMID: 34901050 DOI: 10.3389/fmed.2021.714205] [Reference Citation Analysis]
11 Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS One 2018;13:e0201537. [PMID: 30086150 DOI: 10.1371/journal.pone.0201537] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
12 Merino-Ribas A, Araujo R, Bancu I, Graterol F, Vergara A, Noguera-Julian M, Paredes R, Bonal J, Sampaio-Maia B. Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study. Int Urol Nephrol 2021. [PMID: 34923600 DOI: 10.1007/s11255-021-03091-3] [Reference Citation Analysis]
13 Malberti F. Hyperphosphataemia: Treatment Options. Drugs 2013;73:673-88. [DOI: 10.1007/s40265-013-0054-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
14 Navarro-gonzález J, Donate-correa J, Muros M, García-garcía P, Getino M, García-pérez J, Mora-fernández C. Lanthanum Carbonate Modulates Inflammatory Profile in Hemodialysis Patients: Relationship with Fibroblast Growth Factor-23. Eur J Inflamm 2013;11:75-86. [DOI: 10.1177/1721727x1301100108] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Guida B, Cataldi M, Riccio E, Grumetto L, Pota A, Borrelli S, Memoli A, Barbato F, Argentino G, Salerno G. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study. PLoS One. 2013;8:e73558. [PMID: 24015307 DOI: 10.1371/journal.pone.0073558] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
16 Cozzolino M, Rizzo MA, Stucchi A, Cusi D, Gallieni M. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis. 2012;3:59-68. [PMID: 23251769 DOI: 10.1177/2040622311433771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
17 Marzocco S, Fazeli G, Di Micco L, Autore G, Adesso S, Dal Piaz F, Heidland A, Di Iorio B. Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study). J Clin Med 2018;7:E315. [PMID: 30274359 DOI: 10.3390/jcm7100315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
18 Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 2018;8:CD006023. [PMID: 30132304 DOI: 10.1002/14651858.CD006023.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
19 Jódar-Gimeno E, Muñoz-Torres M. [Vitamin D hormone system and diabetes mellitus: lessons from selective activators of vitamin D receptor and diabetes mellitus]. Endocrinol Nutr 2013;60:87-95. [PMID: 22763025 DOI: 10.1016/j.endonu.2012.04.005] [Reference Citation Analysis]
20 Hsu DC, Sereti I. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs 2016;76:533-49. [PMID: 26915027 DOI: 10.1007/s40265-016-0546-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
21 Smith ER, Pan FFM, Hewitson TD, Toussaint ND, Holt SG. Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial. Kidney Int Rep 2020;5:1432-47. [PMID: 32954068 DOI: 10.1016/j.ekir.2020.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Tsuji Y, Kaji K, Kitade M, Kaya D, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Moriya K, Akahane T, Yoshiji H. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms 2020;8:E925. [PMID: 32575352 DOI: 10.3390/microorganisms8060925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226. [PMID: 24134531 DOI: 10.1186/1471-2369-14-226] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
24 Kanbay M, Onal EM, Afsar B, Dagel T, Yerlikaya A, Covic A, Vaziri ND. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. Int Urol Nephrol. 2018;50:1453-1466. [PMID: 29728993 DOI: 10.1007/s11255-018-1873-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
25 Perry CM, Plosker GL. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease. Drugs 2014;74:771-92. [PMID: 24811546 DOI: 10.1007/s40265-014-0215-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
26 Yuste C, Mérida E, Hernández E, García-Santiago A, Rodríguez Y, Muñoz T, Gómez GJ, Sevillano Á, Praga M. Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J 2017;10:539-44. [PMID: 28852493 DOI: 10.1093/ckj/sfx013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
27 March DS, Graham-Brown MP, Stover CM, Bishop NC, Burton JO. Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options. Biomed Res Int 2017;2017:5765417. [PMID: 28194419 DOI: 10.1155/2017/5765417] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
28 Lenglet A, Fabresse N, Taupin M, Gomila C, Liabeuf S, Kamel S, Alvarez JC, Drueke TB, Massy ZA. Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients? Drugs 2019;79:855-62. [PMID: 31062264 DOI: 10.1007/s40265-019-01118-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
29 Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses 2019;11:E200. [PMID: 30818749 DOI: 10.3390/v11030200] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 28.7] [Reference Citation Analysis]
30 Sharaf El Din UAA, Salem MM, Abdulazim DO. Stop chronic kidney disease progression: Time is approaching. World J Nephrol 2016; 5(3): 258-273 [PMID: 27152262 DOI: 10.5527/wjn.v5.i3.258] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
31 Basutkar RS, Varghese R, Mathew NK, Sankar Indira P, Viswanathan B, Sivasankaran P. Systematic review and meta-analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control. Nephrology (Carlton) 2021. [PMID: 34882904 DOI: 10.1111/nep.14011] [Reference Citation Analysis]
32 Guldris SC, Parra EG, Amenós AC. Gut microbiota in chronic kidney disease. Nefrología (English Edition) 2017;37:9-19. [DOI: 10.1016/j.nefroe.2017.01.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
33 Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS 2013;27:1199-208. [PMID: 23324661 DOI: 10.1097/QAD.0b013e32835ecb8b] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
34 Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657-670. [PMID: 24231662 DOI: 10.1681/asn.2013080905] [Cited by in Crossref: 353] [Cited by in F6Publishing: 201] [Article Influence: 39.2] [Reference Citation Analysis]
35 Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N. Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients. Int Urol Nephrol 2013;45:839-45. [PMID: 22684797 DOI: 10.1007/s11255-012-0211-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
36 Patel L, Bernard LM, Elder GJ. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol 2016;11:232-44. [PMID: 26668024 DOI: 10.2215/CJN.06800615] [Cited by in Crossref: 93] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
37 Wu CL, Wu HM, Chiu PF, Liou HH, Chang CB, Tarng DC, Chang CC. Associations between the duration of dialysis, endotoxemia, monocyte chemoattractant protein-1, and the effects of a short-dwell exchange in patients requiring continuous ambulatory peritoneal dialysis. PLoS One 2014;9:e109558. [PMID: 25286027 DOI: 10.1371/journal.pone.0109558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
38 Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549-1554. [PMID: 24864123 DOI: 10.1093/infdis/jiu305] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
39 Voelkl J, Egli-Spichtig D, Alesutan I, Wagner CA. Inflammation: a putative link between phosphate metabolism and cardiovascular disease. Clin Sci (Lond) 2021;135:201-27. [PMID: 33416083 DOI: 10.1042/CS20190895] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
40 Biruete A, Hill Gallant KM, Lindemann SR, Wiese GN, Chen NX, Moe SM. Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. J Ren Nutr 2020;30:4-10. [PMID: 30846238 DOI: 10.1053/j.jrn.2019.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]